Tenax’s TNX-103 fails primary endpoint in Phase 3 PH-HFpEF trial
Tenax Therapeutics' stock collapsed on August 10, 2026, after the company announced its Phase 3 LEVEL trial of TNX-103 (oral levosimendan) failed to significantly improve walking distance in patients with pulmonary hypertension associated with heart failure compared to placebo, missing its primary endpoint.
